Israeli biopharmaceutical company Compugen, which develops antibody-based cancer treatments, has entered into a commercialization agreement with American pharmaceutical company Bayer HealthCare.
The two companies will work on researching, developing and commercializing Compugen’s treatments, based on immune checkpoint regulators discovered by the company. The deal is worth $500 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Clean Energy Firm Completes Solar Project In North, South Israel
October 15, 2024
Cannabis Therapy Firm: CBD Jab Reduces Pain In Arthritic Dogs
October 15, 2024
US Government Funding Development Of Israeli Ebola Treatment
October 14, 2024
Security Firm Wins Prison Service Contract For Electronic Monitoring
October 14, 2024
Facebook comments